Combination therapy with immune‐modulators and moxifloxacin on fulminant macrolide‐resistant Mycoplasma pneumoniae infection: A case report1. Issue 5 (4th September 2012)

• Record Type: Journal Article
• Authors: Shen, Yuelin; Zhang, Jin; Hu, Yinghui; Shen, Kunling
• Is Part Of: Pediatric pulmonology. Volume 48:Issue 5(2013:May)
• Page Start: 519
• Page End: 522
• Publication Date: 2012-09-04
• Subjects: Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.22650
• Languages: English
• ISSNs: 8755-6863

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>This report entails a case of refractory pneumonia with a wild variety of extra‐pulmonary manifestations due to macrolide‐resistant <italic>Mycoplasma pneumoniae</italic> infection in a 7‐year‐old boy. The diagnosis was based on isolating <italic>M. pneumoniae</italic> through cultivation from the patient's bronchial aspirations at admission and the following susceptibility testing. Initial treatments consisting of a combination of azithromycin and standard‐dosed methylprednisone (2 mg/kg) were completely nonresponsive and the patient's condition deteriorated rapidly. However, methylprednisone pulse therapy (20 mg/kg for 3 days, tapering within 1 month) and intravenous immunoglobulin (1 g/kg/day, two doses), in addition to moxifloxacin (10 mg/kg for 7 days) were remarkably effective and led to a favorable outcome without any observed side effects during inpatient hospitalization and outpatient follow‐up. Pediatr Pulmonol. 2013; 48:519–522. © 2012 Wiley Periodicals, Inc.</p> </abstract>